Summary:
The FDA has recently added warnings to RSV vaccines Abrysvo and Arexvy, citing a potential link to Guillain-Barré Syndrome (GBS) within 42 days of vaccination. Observational studies found 7-9 excess GBS cases per million doses in adults aged 65 and older. Clinical trials and safety reports support this increased risk, though no direct causal relationship has been established. Despite this, the FDA still states the vaccines’ benefits outweigh the risks. Continuous safety monitoring is ongoing.
Abstract:
N/A
Article Publication Date: 07/01/2025
DOI: N/A
